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Abstract
Background: Medication non-adherence has an important impact on treatment efficacy and healthcare burden
across a range of conditions and therapeutic areas. The aim of this analysis was to determine predictors of
non-adherence and impact of non-adherence on treatment response in adults with attention-deficit/hyperactivity
disorder (ADHD).
Methods: Post-hoc analysis of a 13-week randomized, double-blind placebo-controlled study of OROS methylphenidate
(MPH) 54 and 72 mg/day. Primary efficacy variable was the Conners’ Adult ADHD Rating Scale – Screening Version
(CAARS:O-SV). Daily adherence was calculated as average daily adherence (100 × capsules taken/2), with overall
adherence calculated as the average daily adherence. Predictors of adherence were assessed using mixed-effects logistic
regression. Descriptive statistics were generated for change in CAARS:O-SV score for adherent (> 95% adherence) and
non-adherent subjects. Predictors of change were analyzed using a mixed model.
Results: Subjects were allocated to OROS MPH (54 mg, n = 87; 72 mg, n = 92) or placebo (n = 97). Mean adherence
was 92.6% and 93.3% (OROS MPH 54 and 72 mg/day, respectively), versus 97.5% (placebo). Adherence was higher and
less variable in completers. Factors significantly associated with non-adherence included female sex, shorter time since
ADHD diagnosis, higher education level (completion of university) and score on the Drug Use Screening Inventory
psychiatric disorders subscale. Improvements from baseline in CAARS:O-SV score were numerically greater in subjects
defined as adherent than in those who were non-adherent. Significant predictors of CAARS:O-SV change in patients
who completed the study included percentage adherence up to the point of assessment (p < 0.0001), baseline score
(p < 0.0001) and family history of ADHD (p = 0.0003).
Conclusion: The results of this analysis suggest that newly diagnosed patients, those with a high score on the DUSI-R
psychiatric disorder scale, women, and subjects with high educational degrees may be at increased risk of non-
adherence. Clinicians and policymakers should therefore pay special attention to these individuals, as non-adherence is
a significant predictor of reduced response to treatment.
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Background
Medication adherence has an important impact on treat-
ment efficacy and healthcare burden across a range of
conditions and therapeutic areas [1]. Indeed, improving
adherence may have a greater impact on health than
switching to a more potent or effective agent [2]. One
method of improving adherence is by identifying patient
and medication factors that may prevent patients from
taking their medication in an optimal manner [3]. For
example, adherence can be improved by simplifying
medication regimens, particularly in terms of reduced
frequency of dosing [1,4,5].
In a recent systematic review of 11 adherence studies
in adults and children with ADHD, a very wide range was
obtained for the prevalence of medication discontinuation
or non-adherence (13–64%) [6]. Overall, the authors con-
cluded that further studies are needed to investigate the ex-
tent of the problems with adherence in adults with ADHD,
particularly the impact of medication non-adherence on
the symptoms of ADHD and related outcomes.
Previous studies in adults with ADHD have suggested
that adherence is low in this population. In a study in 66
adults receiving short-acting methylphenidate (MPH),
participants reported using their medication as pre-
scribed only half of the time on average (14.5 of 30 days)
[7]. Poor adherence was best predicted by concurrent
illicit substance use; younger age at MPH prescription
was also associated with poor adherence, although this
was not statistically significant. A study of self-reported
adherence in 27 adults with ADHD who participated
in a pilot study showed that mean adherence for the
2-week period before assessment was 86%, with 18% of
the sample reporting less than 80% adherence, and 43%
less than 90% adherence [8]. Educational level was not
associated with adherence, but adherence was negatively
correlated with ADHD symptoms.
According to several published guidelines, MPH is the
treatment of choice for adults with ADHD [9-13]. Short-
acting stimulants, however, require multiple daily intakes,
which may lead to non-adherence, stigma and embarrass-
ment with medication intake, wearing off, and possible
rebound [14,15]. The osmotic release oral system (OROS)
formulation was designed to deliver MPH in a controlled
manner, allowing once-daily dosing in children, adoles-
cents and adults [16,17].
While adherence to protocol in the controlled environ-
ment of a clinical trial is necessarily different from adher-
ence to a medication regimen in real life, analysis of clinical
trial data can provide useful insights into medication adher-
ence and suggest future avenues for research and interven-
tion. LAMDA-II was a 13-week randomized, double-blind,
multicentre study in adults with ADHD randomly allocated
to OROS MPH 54 or 72 mg/day, or placebo [18]. Here we
report a series of post-hoc analyses from LAMDA-II that
were conducted to determine factors affecting adherence
with OROS MPH and the impact of non-adherence on re-
sponse to treatment in terms of ADHD symptoms.
Methods
Study design and subjects
LAMDA-II (EudraCT #: 2007-002111-82) was a multicen-
tre, double-blind, randomized, placebo-controlled, dose–
response study conducted at 42 sites in Europe between
February 2008 and April 2009. After up to 2 weeks of
screening, subjects were randomly allocated to OROS
MPH (54 or 72 mg/day) or matching placebo for 13 weeks.
All patients received two capsules per day (1 × 18 mg + 1 ×
36 mg, 2 × 36 mg or 2 × placebo). Eligible subjects were
adults with a Diagnostic and Statistical Manual of Mental
Disorders (4th ed., Text Revision, DSM-IV-TR) diagnosis of
ADHD, confirmed using Conners’Adult ADHD Diagnostic
Interview Part II (CAADID) for DSM-IV. To be eligible for
the study, subjects were required to have a score of ≥ 24 on
the observer-rated Conners’ Adult ADHD Rating Scale—
Screening Version (CAARS:O-SV). The Structured Clinical
Interview for DSM-IV Axis I disorders (SCID-I) was used
to evaluate the presence of co-morbidities and to exclude
other disorders. The study conforms to the requirements of
the 1964 Declaration of Helsinki. The research protocol
was approved by the ethics committees at each site
(Table 1), and all participants gave written informed
consent. Full details of the study design and eligibility
criteria have been published previously [18].
Assessments
The primary efficacy variable in the study was the
investigator-rated CAARS:O-SV, which was assessed
after 1 week and then every 2 weeks thereafter. The
CAARS:O-SV comprises 18 items corresponding to the
18 DSM-IV–defined ADHD symptoms and provides a
total score and two subscale scores (Inattention and
Hyperactivity/Impulsivity), with higher scores indicating
greater ADHD symptoms [19]. The CAARS:O-SV has
shown very high model fit in healthy control and ADHD
patient samples, and the reliability and cross-cultural
validity of the instrument have been demonstrated [20].
The presence of substance use disorders was assessed
using the Drug Use Screening Inventory Revised (DUSI-R),
a 159-item self-administered instrument [21]. The 159
questions are subdivided into 11 domains: drug and alco-
hol use frequency, substance use, behavior pattern, health
status, psychiatric disorder, social competence, family sys-
tem, school performance, work adjustment, peer relation-
ship and leisure/recreation.
Daily adherence to therapy was calculated as the ratio
of capsules taken on that day to capsules prescribed by
the protocol (i.e. 100 × number of capsules taken on that
day/2). Overall adherence was calculated as the average
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daily adherence during the 13-week double-blind study.
Patients were defined as adherent if their overall adher-
ence was > 95%.
Statistical analysis
For the purposes of this post-hoc analysis, the main ana-
lysis set was defined as all randomized subjects who
received at least one dose of study medication and had
at least one post-baseline efficacy assessment. Because
adherence is strongly related to study discontinuation,
we replicated our analyses on a ‘completers’ subgroup,
which was defined as all subjects in the main analysis set
who completed all CAARS:O-SV assessments as sched-
uled in the study protocol. This analysis served as a sen-
sitivity check for the analysis on the main analysis set, as
any findings from the analyses on the completers cannot
be attributed to (early) discontinuation.
Predictors of daily adherence were assessed using a
mixed-effects logistic regression model. This model is
appropriate for the analysis of a binary variable (adher-
ent/non-adherent), while it also incorporates the longi-
tudinal design (one outcome per day per patient) as a
hierarchical structure in which daily adherence is nested
within patient [22]. In addition, this model allows for the
inclusion of time-varying covariates. The following vari-
ables were included in the model: age; sex; history of
mood or anxiety disorder, country; treatment group;
Table 1 Ethics committees
Country Committee
Norway Regional komité for medisinsk og helsefaglig
forskningsetikk, Sør-Øst-Norge (REK Sør-Øst)
France Comité de Protection des Personnes – Ile de France VI
Sweden Regionala etikprövningsnämnden i Stockholm
Denmark Den Videnskabsetiske Komité for Region Midtjylland
Netherlands UMC St. Radboud
Adviescommissie Mensgebonden
METIGG (Kamer Noord)
Spain Secretaría del CEIC, Servicio Farmacología Clínica
Hospital Clínico San Carlos
Secretario del CEIC, Servicio de Farmacia, Hospital Vall
d’Hebrón
Hospital Gregorio Marañón, Oficina Técnica CEIC-A1
Belgium Ethische Commissie, Sint-Vincentiusziekenhuis vzw.
vzw Emmaüs Ethisch Comité
Comité Ethique, Hôpital Psychiatrique Le Chêne aux
Haies
Faculteit Geneeskunde, Commissie Medische Ethiek/
Klinischonderzoek
UK East London & The City Research, Ethics Committee 1
Cambridgeshire 2 Research Ethics Committee
South West Wales REC
Finland Pohjois-Pohjanmaan sairaanhoitopiirin eettinen
toimikunta, Hallintokeskus
Germany Ethik-Kommission des Landes Berlin
Ethik-Kommission der Ärztekammer, Schleswig-Holstein
Ethik-Kommission der Medizinischen, Fakultät der
Universität Duisburg-Essen, Universitätsklinikum
Ethik-Kommission der Bayerischen Landesärztekammer
Ethik-Kommission bei der Ärztekammer des Saarlandes
Ethik-Kommission der Albrecht-Ludwigs-Universität
Freiburg
Ethikkommission der Medizinischen, Fakultät der LMU
München
Medizinische Ethik-Kommission II der Fakultät für
Klinische Medizin, Mannheim der Ruprecht-Karls-
Universität Heidelberg
Ethikkommission der Medizinischen Fakultät der
Bayerischen Julius-Maximilians-Universität Würzburg
Ethikkommission der Medizinischen Fakultät der
Heinrich-Heine-Universität
Switzerland Etikkommission bei der Basel EKBB
Table 2 Baseline characteristics and disease history
Characteristic Placebo OROS MPH OROS MPH
(n = 97) 54 mg (n = 87) 72 mg (n = 92)
Age, years
Mean ± SD 35.5 ± 8.8 35.5 ± 11.8 35.8 ± 10.1
Median (range) 36 (18-57) 33 (18-64) 35 (18-60)
Sex, n (%)
Female 45 (46.4) 44 (50.6) 42 (45.7)
Male 52 (53.6) 43 (49.4) 50 (54.3)
Educational status, n (%)
Primary school 7 (7.2) 8 (9.2) 8 (8.7)
Secondary
school
40 (41.2) 24 (27.6) 29 (31.5)
High school 29 (29.9) 29 (33.3) 26 (28.3)
University 21 (21.6) 26 (29.9) 29 (31.5)
Age at ADHD
diagnosis, years
(mean ± SD)
31.9 ± 12.8 31.2 ± 15.1 32.4 ± 13.0
Adult ADHD type, n (%)
Combined 73 (75.3) 59 (67.8) 62 (67.4)
Predominantly
inattentive
23 (23.7) 26 (29.9) 28 (30.4)
Predominantly
hyperactive–
impulsive
1 (1.0) 2 (2.3) 2 (2.2)
Family history of
ADHD, n (%)
53 (54.6) 55 (63.2) 52 (56.5)
History of mood
and anxiety
disorder, n (%)
50 (51.5) 39 (44.8) 39 (42.4)
Baseline CAARS-O:
SV (mean ± SD)
36.5 ± 6.1 35.7 ± 6.8 37.3 ± 6.4
Kooij et al. BMC Psychiatry 2013, 13:36 Page 3 of 10
http://www.biomedcentral.com/1471-244X/13/36
adult ADHD subtype (predominantly inattentive, pre-
dominantly hyperactive–impulsive or combined); age at
ADHD diagnosis; time since ADHD diagnosis; family
history of ADHD; highest level of education completed;
employment status; prior use of MPH; concomitant
treatment for anxiety disorder; concomitant treatment
for depression; baseline CAARS:O-SV total score; DUSI
subscale scores; and day of the week.
To explore the impact of adherence on efficacy, de-
scriptive statistics were generated for change in CAARS:
O-SV score from baseline for adherent (> 95% overall
adherence) and non-adherent subjects. In addition, a
statistical analysis on potential predictors of change in
CAARS:O-SV score on all time points per patient during
treatment was performed using a mixed model. The
following independent variables were considered: prior
adherence (i.e., percentage adherence in the period
before each CAARS:O-SV assessment); day of the week
and season as time-varying covariates, age, sex, country,
treatment group, ADHD subtype, time since ADHD
diagnosis, family history of ADHD (yes or no), highest
level of education completed and employment status
(employed vs. unemployed), baseline CAARS score, his-
tory of mood and anxiety disorder (yes or no), prior use
of MPH (yes or no), age at ADHD diagnosis, all DUSI
scales, concomitant treatment for anxiety disorder (yes
or no) and concomitant treatment for depression (yes or
no), as independent variables.
The following testing strategy was followed for both
statistical models. All independent variables were first
tested for univariately, and included in the multivariate
model in case of p < 0.20. Interaction of each independent
variable with treatment group was tested in the multivari-
ate model and kept in the model if p < 0.1. Independent
variables with p > 0.1 were removed from the multivariate
model in a backwise fashion, and variables with the largest
p-value were removed first. Only the final model is pre-
sented in this manuscript. Restricted likelihood distance
and Cook’s d were used to detect influential observations.
No influential observations were dropped.
Results
Subjects and disposition
The main analysis set consisted of 276 subjects allocated to
OROS MPH 54 mg (n = 87) or 72 mg (n = 92), or to pla-
cebo (n = 97). Baseline characteristics are shown in Table 2.
The completer population included 67 subjects (69.1%) in
the placebo arm, 55 subjects (63.2%) in the 54-mg arm and
54 subjects (58.6%) in the 72-mg arm. Reasons for discon-
tinuation included lack of efficacy (n = 14; 14%) in the
Table 3 Reasons for discontinuation during the study
Reason for discontinuation,
n (%)
Placebo OROS MPH
(n = 97) 54 mg/day 72 mg/day
(n = 87) (n = 92)
Discontinued 29 (29.9) 32 (36.8) 37 (40.2)
Adverse event 2 (2.1) 15 (17.2) 19 (20.7)
Lack of efficacy 14 (14.4) 1 (1.1) 4 (4.3)
Noncompliance 3 (3.1) 5 (5.7) 5 (5.4)
Consent withdrawal 4 (4.1) 2 (2.3) 3 (3.3)
Loss to follow-up 5 (5.2) 1 (1.1) 0
Sponsor’s decision 0 2 (2.3) 0
Ineligibility to continue the study 0 1 (1.1) 1 (1.1)
Other 1 (1.0) 5 (5.7) 5 (5.4)
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Figure 1 Mean adherence in patients who completed the study and in those who discontinued.
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placebo arm, and adverse events in the OROS MPH
54-mg (n = 15; 17%) and 72-mg (n = 19; 21%) arms
(Table 3). Full details of the study population have been
published previously [5].
Adherence
Mean (± SD) adherence was 92.6% ± 17.6 and 93.3% ±
13.4 in the 54- and 72-mg/day OROS MPH groups,
respectively, versus 97.5% ± 6.8 in the placebo group
(main analysis set). Mean adherence was higher and less
variable in the completers subgroup compared with
those who discontinued, especially in those receiving
active treatment (Figure 1).
Overall adherence with study medication intake of 100%
was observed in 55.2% (n = 48), 44.6% (n = 41) and 57.7%
(n = 56) of subjects receiving OROS MPH 54 or 72 mg, or
placebo, respectively (one subject in each of the placebo
and OROS MPH 54-mg arms reported taking four cap-
sules per day on one day and had no record of missed
doses, and therefore had an adherence > 100%) (Figure 2).
No systematic trend in adherence could be found.
Predictors of adherence
In the mixed-effects logistic regression model on daily
adherence, several significant predictors of adherence
were identified (Table 4). Overall, men tended to be
more adherent than women (p = 0.0892; main analysis
set), and subjects receiving placebo were more adherent
than those receiving OROS MPH (p = 0.0221 and p =
0.0371 for the 54-mg and 72-mg doses, respectively).
Adherence increased with increasing time since diagno-
sis of ADHD (p = 0.007), and subjects who completed
university were significantly less likely to be adherent
than those who completed high school (p = 0.0284). The
higher (i.e. more problematic) the score on the DUSI
psychiatric disorder scale at baseline, the less likely sub-
jects were to be adherent (p = 0.0252). In the completer
analysis, there was no significant difference in adherence
between OROS MPH groups and placebo (Table 4). In
addition, male sex, DUSI psychiatric disorder score and
time since ADHD diagnosis were no longer significantly
related to adherence (and therefore do not appear in the
final model, as shown in Table 4), but DUSI health
70
60
50
40
30
20
10
0
Pa
tie
nt
s 
(%
)
>100% 100% 90 to <100% 80 to <90% 70 to <80% 60 to <70% 50 to <60% 0 to <50%
Overall adherence
2.1
Placebo (n = 97)
OROS MPH 54 mg (n = 87)
OROS MPH 72 mg (n = 92)
5.7 4.3
1.0 1.1
4.3
1.0
3.4 4.3
1.0
3.4 2.2 00
3.4 2.2
26.4
38.036.1
44.6
55.2
57.7
1.11.0
Figure 2 Overall adherence.
Table 4 Predictors of adherence
Variable Main analysis set Completer population
Point
estimate
p-value Point
estimate
p-value
Treatment: OROS
MPH 54 mg
−1.0472 0.0221 −0.0645 0.7712
Treatment: OROS
MPH 72 mg
−0.9122 0.0371 −0.2533 0.2244
Sex (Male) 0.6374 0.0892 – –
Country –a NS –b –b
DUSI: psychiatric
disorder
−0.0296 0.0252 – –
DUSI health status −0.0238 0.0563 −0.0182 0.0012
Education level:
primary
0.1759 0.8102 0.9829 0.0107
Education level:
secondary
0.4870 0.2963 0.1399 0.5012
Education level: high
school
1.0683 0.0284 1.2055 < 0.0001
Time since ADHD
diagnosis
0.0770 0.0070 – –
a Point estimates for individual countries ranged from −0.4944 to +2.6307;
none were statistically significant.
b Point estimates for individual countries ranged from −2.1366 to +3.2225; values
were statistically significant for France (point estimate: −2.1366 [p < 0.0001]) and
Sweden (estimate: −1.4175 [p = 0.0074]).
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status score at baseline was. As in the overall analysis,
subjects who completed university were significantly less
likely to be adherent than those who completed their
education after high school (p < 0.0001) or primary
school (p = 0.0197).
Impact of non-adherence on efficacy
For subjects receiving OROS MPH, decreases (improve-
ments) from baseline in CAARS:O-SV score were nu-
merically greater in subjects defined as adherent than in
those who were not, in both the main analysis set and
completer population (Figure 3).
In the main analysis set, significant predictors of
change in CAARS:O-SV score (Table 5) included base-
line CAARS:O-SV score (p < 0.0001), study time point
(p < 0.0001) and percentage overall adherence in the
study before the CAARS:O-SV assessment (p < 0.0001).
The decrease in CAARS:O-SV was significantly larger
for both MPH groups versus placebo. The greatest
improvement in CAARS:O-SV score occurred early in
the study, and the decrease in CAARS:O-SV over time
differed between the treatment groups, although the
level of adherence, particularly in the 72-mg arm,
affected change in CAARS:O-SV throughout the study
(Figure 4). Finally, subjects with a family history of
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Figure 3 Mean (95% CI) change from baseline to endpoint in CAARS:O-SV score. Subjects defined as adherent (> 95% overall adherence)
or non-adherent in the (a) main analysis set; and (b) completer population.
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ADHD showed greater improvement (p = 0.0104), and
the longer the time since diagnosis of ADHD, the less
the degree of improvement (p = 0.0072).
In the completer population, higher baseline CAARS:
O-SV score (p < 0.0001), higher percentage prior adher-
ence (p < 0.0001), longer time in study (p < 0.01 for
72-mg arm from Week 5 onwards and p < 0.05 for
54-mg arm from Week 7 onwards) and family history of
ADHD (p = 0.0003) were significant predictors of
change in CAARS:O-SV score (Table 6). Again, both
MPH groups showed a significantly larger improvement
compared with placebo, and the decrease in CAARS:O-SV
score over time was different between the treatment
groups.
Discussion
In the present study, adherence to OROS MPH treat-
ment was generally high, as might be expected in a
randomized, placebo-controlled trial. Self-reported ad-
herence in real-life settings is, however, substantially
lower [7,8]. Factors associated with reduced adherence
in the present study included score on the DUSI-R psy-
chiatric disorder scale, completing university versus high
school, and shorter time since diagnosis of ADHD; and
men were more adherent than women. Adherence was
also higher in subjects receiving placebo than in those
receiving OROS MPH. In particular, the discontinuers in
the MPH groups had a low adherence. In the patients
who completed the trial, there was no difference in ad-
herence between the treatment groups. In previous stud-
ies that looked at factors associated with adherence in
adults with ADHD, adherence was significantly corre-
lated with ADHD symptoms, substance abuse and
younger age [7,8]. These studies had small sample sizes,
however, and were based on patient reports of adher-
ence, so direct comparison with the present study is
difficult.
It is possible that some of the factors identified as con-
tributing to non-adherence (e.g. education, time since
diagnosis) may, in fact, reflect some degree of misdiag-
nosis of ADHD, with subsequent impact on adherence
and study discontinuation. For example, the disorder is
highly genetic, is lifelong, and is likely to interfere with
completion of education. Furthermore, some of its
symptoms may be mimicked by other psychiatric disor-
ders (e.g. anxiety or depression may produce difficulty
concentrating or maintaining focus on current activities).
It is important to note, however, that a short time since
diagnosis is common in adults with ADHD, as they are
unlikely to have been diagnosed during childhood in
Europe. The impact of short time since diagnosis on
adherence may therefore reflect lower acceptance of the
disorder and less motivation for treatment. Similarly,
lack of family history could suggest a subgroup who have
ADHD that is less heritable, or where the patient does
not know or realise that ADHD is present in the family
(not uncommon when one is not yet familiar with the
clinical presentation of ADHD). Psychiatric comorbidity
in patients with ADHD may lead to low adherence
through impact of MPH on other symptoms, such as
anxiety or depression, while substance abuse is clearly
associated with non-attendance, stagnation of treatment
Table 5 Regression analysis of variables affecting change
in CAARS:O-SV score (main analysis set)
Estimate p-value Difference in
least squares
means
p-value
Baseline –0.4203 0.0007 – –
Prior adherence –0.0145 0.7530 – –
Treatment group:
54 mg 2.6840 0.7436 –2.7528 0.0145
72 mg 12.2774 0.1441 –4.5799 < 0.0001
Baseline × Treatment group:
54 mg 0.1473 0.3922 – –
72 mg –0.2533 0.1448 – –
Time point (versus Week 13)
Week 1 3.9770 0.0003 7.1825 0.0001
Week 3 1.8149 0.0767 3.3609 < 0.0001
Week 5 1.5768 0.0923 2.8016 < 0.0001
Week 7 –0.0884 0.9186 0.8591 0.1023
Week 9 0.3289 0.6653 0.5197 0.2625
Time point × Treatment group
Week 1 × 54 mg 4.6804 0.0037 0.3118 0.8088
Week 1 × 72 mg 4.8763 0.0022 –1.6352 0.1917
Week 3 × 54 mg 2.1269 0.1603 –2.2417 0.0908
Week 3 × 72 mg 2.5112 0.0914 –4.0003 0.0020
Week 5 × 54 mg 1.8791 0.1753 –2.4895 0.0667
Week 5 × 72 mg 1.7954 0.1878 –4.7161 0.0004
Week 7 × 54 mg 0.7517 0.5571 –3.6169 0.0101
Week 7 × 72 mg 2.0907 0.0980 –4.4208 0.0013
Week 9 × 54 mg 0.2565 0.8192 –4.1121 0.0045
Week 9 × 72 mg 0.3160 0.7777 –6.1955 < 0.0001
Treatment group × adherence
54 mg –0.1276 0.0197 – –
72 mg –0.0976 0.0721 – –
Female sex –1.5429 0.0949 – –
No family history
of ADHD
2.4018 0.0104 – –
Time since ADHD
diagnosis
0.1403 0.0072 – –
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and interference with evaluation of medication. Simi-
larly, completion of higher education does not necessar-
ily point to an incorrect diagnosis; more intelligent
individuals with ADHD tend to achieve higher levels of
education than those of lower intelligence, yet still ex-
perience impairments relative to their potential.
The analysis of change in CAARS:O-SV showed that
lower adherence was significantly associated with less
improvement in ADHD symptoms, particularly in sub-
jects receiving OROS MPH. The other notable predictor
of treatment efficacy was the presence of a family history
of ADHD; this may be because subjects with affected
family members may have had access to greater support.
As expected, baseline CAARS:O-SV score was also sig-
nificantly associated with improvement in CAARS:O-SV,
as was time since ADHD diagnosis. As non-adherence is
related to study discontinuation, the analysis was
repeated on study completers and it was again shown
that non-adherence significantly affected the level of im-
provement in CAARS:O-SV. There were, however differ-
ences between the main analysis set and the completer
population, which may be related to the impact of dis-
continuation in the main analysis set, and may also have
been affected by the decreased statistical power in the
smaller population or the lower variability in adherence
in the completer population.
A main strength of the present study is the size of the
cohort, although it should be noted that this was a post-
hoc analysis and the study was not designed to assess
adherence. In addition, identification of factors that are
statistically associated with adherence does not always
translate into clinical relevance [23]. A randomized, con-
trolled trial may not be the best setting in which to evaluate
adherence, which may be higher than in the ‘real world,’ as
suggested by previous small studies in adults with ADHD
[7,8]. The generalizability of the study findings may there-
fore be limited to clinical trials in which patient inclusion is
strictly controlled, excluding patients with, for example,
psychiatric co-morbidity. It should also be noted that there
are numerous possible methods of assessing adherence,
including patient reports, carer reports, pill counts, phar-
macy data, electronic measurement and measurement of
plasma drug levels; but none of these methods is ideal. In
the present study, it is possible that measurements of ad-
herence were affected by patients deliberately returning
fewer capsules to give the impression that their adherence
was higher [24]. Furthermore, one important predictor of
adherence—number of medication doses—could not be
analysed in the present study, as all patients received a
single daily dose of OROS MPH or placebo. Finally, the po-
tential impact of selecting a cut-off for the definition of
‘adherent’ other than 95% was not investigated.
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Concepts of adherence are continuing to evolve, and the
factors involved in adherence can be extended to a broader
concept of ‘concordance,’ as recently introduced by David
Coghill (J. J. S. Kooij; personal communication). This
describes something beyond adherence, namely mutual
agreement between patient and physician with the need for
medication and the correct way to take it. Patient educa-
tion is a key part of achieving concordance.
Conclusions
The results of this study suggest that women, newly
diagnosed patients, those with a high score on the
DUSI-R psychiatric disorder scale, and subjects with
high educational degrees, at least in the context of this
study, seem to have a higher risk of non-adherence. In
this regard, routine assessment of these possible predic-
tors—as well as patients’ attitudes towards medication,
systematic evaluation of target symptoms and side
effects, and adherence by patient self-report and follow-
up with patients at risk of poor adherence—may be valu-
able [23]. Furthermore, physicians and other healthcare
workers should encourage good adherence by education
of, and discussion with, the patient about all aspects
involved in treatment, to maximize treatment efficacy.
While adherence with OROS MPH in this study was
generally high, non-adherence was associated with a
reduced response to treatment, as measured by the
CAARS:O-SV.
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